Zwitterionic fluorescent compound, preparation method therefor and use thereof
By modifying the sulfonic acid group and connecting quaternary ammonium fragments on indole compounds, zwitterionic fluorescent compounds were developed, which solved the problems of easy degradation and batch instability of organic macromolecular probes, and achieved high sensitivity and biocompatibility fluorescent probes are used for the early diagnosis and treatment of urinary diseases.
Patent Information
- Application Number
- PCT/CN2023/127719
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-23
- Filing Date
- 2023-10-30
- Publication Date
- 2024-11-28
AI Technical Summary
Existing organic macromolecule renal clearance fluorescent probes are prone to degradation in the body and the product batch is unstable, affecting the diagnosis and treatment of urinary diseases.
Develop a zwitterionic fluorescent compound that enhances its biologic by connecting sulfonic acid groups to quaternary ammonium-containing fragments on the structure of the indole compounds and connecting -OH, -NH2 or biomarker-responsive groups at specific substitutions Compatibility, optical stability and water solubility form fluorescent probes with high sensitivity.
Early diagnosis and intraoperative navigation of fluorescent probes are achieved, the accuracy and therapeutic effect of disease diagnosis are improved, and the efficiency of renal clearance is good.
Smart Images

Figure CN2023127719_28112024_PF_FP_ABST
Abstract
Description
A zwitterionic fluorescent compound and its preparation method and application Technical Field
[0001] The present invention relates to the field of biomedical technology, and more particularly to a zwitterionic fluorescent compound and a preparation method and application thereof. Background Art
[0002] The urinary system is composed of the kidneys, ureters, bladder, and urethra, and is an important excretion pathway for metabolic products in the human body. During the excretion process, abnormal metabolic waste, foreign microorganisms, drugs, etc. can easily cause infection and damage to surrounding tissues and cells, leading to a series of diseases. Currently, the clinical diagnosis of urinary system diseases often relies on traditional imaging methods. However, these methods have defects such as high ionizing radiation, low sensitivity, invasiveness and high cost, making it difficult to diagnose and intervene early. Compared with traditional imaging technology, optical imaging / detection technology has the advantages of high sensitivity, strong specificity, high safety, and easy popularization. Therefore, the use of non-invasive, non-ionizing radiation, highly specific and sensitive fluorescence imaging technology to detect urinary system diseases has excellent application prospects.
[0003] Currently, probes used for kidney disease detection primarily include inorganic nanoprobes and organic molecular probes. The metabolism of inorganic nanoprobes is limited by the pore size of the glomerular basement membrane, resulting in strict selectivity for nanoprobe size. Only inorganic nanoparticles with a hydrated diameter less than 6 nm and low protein binding can be effectively excreted through the kidneys. Furthermore, inorganic nanomaterials have a slow metabolism rate and can be trapped and accumulated in the liver's endothelial reticular system during circulation, leading to long-term, potential biotoxicity. Furthermore, the preparation of inorganic nanoprobes is limited in scale, expensive, and poses difficulties in synthetic production reproducibility and quantification. In contrast, organic molecular probes offer advantages such as rapid metabolism, high biocompatibility, and structural modifiability, resulting in a wide range of applications in the biomedical field, including cell imaging, tumor diagnosis and treatment, and clinical intraoperative navigation. Renally cleared fluorescent probes constructed using organic molecules are primarily constructed by coupling with hydrophilic macromolecules (such as polyethylene glycol, cyclodextrin, and polysaccharides) to achieve good water solubility and renal metabolism. For example, patent publication number CN115947946A provides a hydrophilic organic macromolecule renal-cleared fluorescent probe. However, due to the presence of numerous complex glycoprotein enzymes in the body, molecular probes labeled with such hydrophilic organic macromolecules are susceptible to degradation in vivo. Furthermore, fluorescently conjugated hydrophilic macromolecules are typically polymers, which often leads to unstable synthesis processes and significant variability between batches, hindering subsequent biological applications.
[0004] Therefore, the development of single-molecule, label-free, renal-cleared fluorescent probes is of great significance for the diagnosis and treatment of urinary system diseases.
[0005] Summary of the Invention
[0006] The primary purpose of the present invention is to overcome the problems of the existing organic macromolecular renal-cleared fluorescent probes being easily degraded in the body and having unstable product batches, and to provide a zwitterionic fluorescent compound.
[0007] A further object of the present invention is to provide a method for preparing the above-mentioned zwitterionic fluorescent compound.
[0008] A further object of the present invention is to provide use of the above-mentioned zwitterionic fluorescent compound or its pharmaceutically acceptable salt, solvate, enantiomer, diastereomer, or tautomer in the preparation of a fluorescent probe.
[0009] The above-mentioned purpose of the present invention is achieved through the following technical solutions:
[0010] A zwitterionic fluorescent compound having a structure shown in any one of formulas (I) to (V):
[0011] Among them, R1 is R2 is -OH, -NH2, A is a self-eliminating group, B is a biomarker response group; n is an integer of 0 to 50, n1 is an integer of 0 to 20, and n2 is an integer of 0 to 20.
[0012] The present invention uses a specific main structure as a fluorophore (chromophore), attaches a specific R2 group (-OH, -NH2, or containing a biomarker-responsive group) to a specific substitution position at one end of the main structure, and attaches a sulfonic acid group and a quaternary ammonium-containing fragment to specific substitution positions at the other end of the main structure, respectively, to obtain a zwitterionic fluorescent compound. The fluorophore has a good quantum yield, and the biomarker-responsive group can be activated by the corresponding biomarker, thereby causing changes in the molecular structure and optical properties, generating a stronger fluorescent signal, and can be monitored in real time using fluorescence imaging technology. The zwitterionic fluorescent compound not only has high sensitivity, good biocompatibility, and optical stability, but also has good water solubility and renal clearance efficiency due to its coordination with the substituent group or fragment.
[0013] It should be noted that, in formula (I) to formula (V) All of them belong to the structure of indole compounds and can be equivalently replaced in the present invention; Compare The more benzene rings there are, the stronger the conjugation effect is. Both of them have conjugation effect. As the number of phenyl groups increases, the ultraviolet absorption wavelength gradually increases. They can also emit fluorescence, and the fluorescence wavelength also gradually increases.
[0014] The zwitterionic fluorescent compound provided by the present invention can be used as a fluorescent probe and prepared into a preparation for a variety of administration modes (intravenous injection, intraperitoneal injection or spraying). Taking intravenous injection as an example, after intravenous injection, the zwitterionic fluorescent compound of the present invention is very low in healthy tissue biomarker expression, and the biomarker response group of the fluorescent probe is not activated, and no change in the probe electron cloud density occurs, so no obvious fluorescent optical signal is detected in healthy tissue. When the urinary system is lesioned, biomarkers are expressed in large quantities, and the zwitterionic fluorescent compound metabolized by the kidney is activated, releasing a strong fluorescent signal, which can be monitored in real time by fluorescence imaging, realizing dynamic monitoring of urinary system lesion sites and visual identification of lesion areas, providing more accurate guidance for the precision treatment of surgery, to improve surgical efficacy and patient prognosis, and is expected to provide a new auxiliary method for human disease diagnosis and treatment.
[0015] Preferably, the self-eliminating group A is
[0016] It will be appreciated that the self-eliminating group A is When the left connection site is connected to the biomarker response group B; the self-eliminating group A is When the left connecting site is connected to B; the self-eliminating group A is When , the right joining site is connected to B.
[0017] The biomarker response group B can be selected according to different target biomarkers. The present invention provides a series of different biomarker response groups.
[0018] Preferably, the biomarker response group B is
[0019] After research, the relationship between the above biomarker response groups and the specific excitation between biomarkers is as follows:
[0020] Preferably, n is an integer from 1 to 20.
[0021] Preferably, n1 is an integer from 1 to 10.
[0022] Preferably, n2 is an integer from 1 to 10.
[0023] The preparation method of the above-mentioned zwitterionic fluorescent compound comprises the following steps:
[0024] S1. Compound 1 represented by formula (1) and compound 6 represented by formula (6) undergo condensation reaction to obtain compound 8 represented by formula (8);
[0025] or the compound 1 represented by formula (1) and the compound 7 represented by formula (7) undergo a condensation reaction to obtain the compound 9 represented by formula (9);
[0026] Or the compound 2 represented by formula (2) and the compound 6 represented by formula (6) undergo a condensation reaction to obtain the compound 12 represented by formula (12);
[0027] Or compound 2 represented by formula (2) and compound 7 represented by formula (7) undergo condensation reaction to obtain compound 13 represented by formula (13);
[0028] Or the compound 3 represented by formula (3) and the compound 6 represented by formula (6) undergo condensation reaction to obtain the compound 16 represented by formula (16);
[0029] or the compound 3 represented by formula (3) and the compound 7 represented by formula (7) undergo a condensation reaction to obtain the compound 17 represented by formula (17);
[0030] Or the compound 4 represented by formula (4) and the compound 6 represented by formula (6) undergo condensation reaction to obtain the compound 20 represented by formula (20);
[0031] Or compound 4 represented by formula (4) and compound 7 represented by formula (7) undergo condensation reaction to obtain compound 21 represented by formula (21);
[0032] Or the compound 5 represented by formula (5) and the compound 6 represented by formula (6) undergo condensation reaction to obtain the compound 24 represented by formula (24);
[0033] Or the compound 5 represented by formula (5) and the compound 7 represented by formula (7) undergo condensation reaction to obtain the compound 25 represented by formula (25);
[0034] S2. Compound 8 undergoes a demethylation reaction to obtain compound 10 represented by formula (10);
[0035] Or compound 12 undergoes a demethylation protection reaction to obtain compound 14 represented by formula (14);
[0036] Or compound 16 undergoes a demethylation reaction to obtain compound 18 represented by formula (18);
[0037] Or compound 20 undergoes a demethylation protection reaction to obtain compound 22 represented by formula (22);
[0038] Or compound 24 undergoes a demethylation protection reaction to obtain compound 26 represented by formula (26);
[0039] Or compound 9 is subjected to reduction reaction to obtain compound 11 represented by formula (11);
[0040] Or compound 13 is subjected to reduction reaction to obtain compound 15 represented by formula (15);
[0041] Or compound 17 is subjected to reduction reaction to obtain compound 19 represented by formula (19);
[0042] Or compound 21 is subjected to reduction reaction to obtain compound 23 represented by formula (23);
[0043] Alternatively, compound 25 is subjected to a reduction reaction to obtain compound 27 represented by formula (27);
[0044] S3. Compound 10 undergoes a substitution reaction with R2-H to obtain a zwitterionic fluorescent compound as shown in formula (I);
[0045] Alternatively, compound 14 undergoes a substitution reaction with R2-H to obtain a zwitterionic fluorescent compound as shown in formula (II);
[0046] Alternatively, compound 18 undergoes a substitution reaction with R2-H to obtain a zwitterionic fluorescent compound as shown in formula (III);
[0047] Alternatively, compound 22 undergoes a substitution reaction with R2-H to obtain a zwitterionic fluorescent compound as shown in formula (IV);
[0048] Alternatively, compound 26 undergoes a substitution reaction with R2-H to obtain a zwitterionic fluorescent compound as shown in formula (V);
[0049] Or compound 11 undergoes a condensation reaction with R2-H to obtain a zwitterionic fluorescent compound as shown in formula (I);
[0050] Alternatively, compound 15 reacts with R2-H to produce a zwitterionic fluorescent compound as shown in formula (II);
[0051] Or compound 19 undergoes condensation reaction with R2-H to obtain a zwitterionic fluorescent compound as shown in formula (III)
[0052] Or compound 23 undergoes a condensation reaction with R2-H to obtain a zwitterionic fluorescent compound as shown in formula (IV);
[0053] Alternatively, compound 27 reacts with R2-H to produce a zwitterionic fluorescent compound as shown in formula (V);
[0054] Preferably, the condensation reaction in step S1 is carried out at a temperature of 45 to 100° C. and for a time of 5 to 12 hours.
[0055] Preferably, the solvent used in the condensation reaction in step S1 is one or more of anhydrous ethanol, anhydrous methanol, N,N-dimethylformamide or acetic anhydride, and the activating agent used is one or more of potassium carbonate, cesium carbonate, sodium acetate or potassium acetate.
[0056] Preferably, the temperature of the demethylation reaction in step S2 is 0-30° C., and the time is 5-12 h; the temperature of the reduction reaction in step S2 is 45-100° C., and the time is 5-12 h.
[0057] Preferably, the solvent used in the demethylation reaction in step S2 is one or more of ethanol, dichloromethane, methanol or N,N-dimethylformamide, and the activating agent used is one or more of boron tribromide, aluminum chloride, sodium ethanethiolate or trimethylsilyl iodide; the solvent used in the reduction reaction in step S2 is one or more of ethanol, methanol, N,N-dimethylformamide or water, and the reducing agent used is one or more of palladium carbon, hydrogen, stannous chloride or iron powder.
[0058] Preferably, the temperature of the substitution reaction in step S3 is 45-100° C., and the time is 5-12 h; the temperature of the condensation reaction in step S3 is 0-45° C., and the time is 8-24 h.
[0059] Preferably, the solvent used for the substitution reaction in step S3 is one or more of anhydrous methanol, anhydrous N,N-dimethylformamide, anhydrous acetonitrile or anhydrous tetrahydrofuran; the solvent used for the condensation reaction in step S3 is one or more of anhydrous methanol, anhydrous N,N-dimethylformamide, anhydrous dichloromethane or anhydrous acetonitrile, the condensation reagent used is one or more of 2-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HATU), 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDCI), dicyclohexylcarbodiimide (DCC) or benzotriazol-1-yl-oxytripyrrolidinophosphine hexafluorophosphate (PyBop), and the activator used is one or more of potassium carbonate, N,N-diisopropylethylamine, triethylamine, pyridine or trimethoprim.
[0060] Preferably, the compound 2 in step S1 is prepared by the following steps:
[0061] S11. Compound 28 represented by formula (28) undergoes substitution reaction with compound 29 represented by formula (29) to obtain compound 2;
[0062] More preferably, the substitution reaction in step S11 is carried out at 80-150° C. for 24-72 h, and the solvent is one or more of N,N-dimethylformamide, toluene or o-dichlorobenzene.
[0063] Preferably, the compound 3 in step S1 is prepared by the following steps:
[0064] S12. Compound 30 represented by formula (30) undergoes substitution reaction with compound 31 represented by formula (31) to obtain compound 3;
[0065] More preferably, the substitution reaction temperature in step S12 is 80-150° C., the time is 24-72 h, and the solvent is one or more of N,N-dimethylformamide, toluene or o-dichlorobenzene;
[0066] Preferably, the compound 7 in step S1 is prepared by the following steps:
[0067] S13. Compound 32 represented by formula (32) undergoes bromination reaction to obtain compound 33 represented by formula (33);
[0068] S14. Compound 33 reacts with compound 34 represented by formula (34) to form a ring to obtain compound 7;
[0069] More preferably, the bromination reaction temperature in step S13 is 0-30° C., the time is 4-12 h, and the solvent is one or more of N,N-dimethylformamide, dichloromethane, tetrahydrofuran or acetonitrile;
[0070] More preferably, the cyclization reaction temperature in step S14 is 0-30° C., the time is 4-12 h, the solvent is one or more of N,N-dimethylformamide, dichloromethane, tetrahydrofuran or acetonitrile, and the activating agent is one or more of potassium carbonate, cesium carbonate, sodium acetate or potassium acetate.
[0071] The use of the above-mentioned zwitterionic fluorescent compound or its pharmaceutically acceptable salt, solvate, enantiomer, diastereomer, tautomer in the preparation of fluorescent probes also falls within the protection scope of the present invention.
[0072] Preferably, the fluorescent probe is a renal-cleared fluorescent probe.
[0073] Preferably, the fluorescent probe is a constantly-on fluorescent probe or an excitation fluorescent probe.
[0074] Preferably, the pharmaceutically acceptable salt is hydrochloride, hydrobromide, nitrate, methylnitrate, sulfate, bisulfate, aminosulfate, phosphate, acetate, glycolate, phenylacetate, propionate, butyrate, isobutyrate, valerate, maleate, hydroxymaleate, acrylate, fumarate, malate, tartrate, citrate, salicylate, para-aminosalicylate, glycolate, lactate, heptanoate, phthalate, oxalate, succinate, benzoate, o-acetyl At least one of oxybenzoate, chlorobenzoate, methylbenzoate, dinitrobenzoate, hydroxybenzoate, methoxybenzoate, mandelate, tannate, formate, stearate, ascorbate, palmitate, oleate, pyruvate, bishydroxynaphthoate, malonate, laurate, glutarate, glutamate, propionate lauryl sulfate, methanesulfonate, ethanesulfonate, 2-hydroxyethanesulfonate, benzenesulfonate, p-aminobenzenesulfonate, p-toluenesulfonate (toluenesulfonate), or naphthalene-2-sulfonate.
[0075] Compared with the prior art, the present invention has the following beneficial effects:
[0076] The zwitterionic fluorescent compounds provided by the present invention use derivatives of hemicyanine dye structures as fluorophores, modify the indole ring with a sulfonic acid group, and connect R2 groups (-OH, -NH2, or containing a biomarker response group) and quaternary ammonium-containing fragments at both ends. They not only have high sensitivity, good biocompatibility and optical stability, but also have good water solubility and renal clearance efficiency through coordination with substituted groups or fragments. As fluorescent probes, they can more accurately diagnose diseases early, navigate intraoperative treatments, and evaluate tissue and organ function. They may play an important role in future medical optical examinations and have excellent application prospects. BRIEF DESCRIPTION OF THE DRAWINGS
[0077] FIG1 is a schematic diagram of the preparation method of the zwitterionic fluorescent compound ZWCYOH1 of Example 1;
[0078] FIG2 is a schematic diagram of the preparation method of the zwitterionic fluorescent compound ZWCYOH2 of Example 2;
[0079] FIG3 is a schematic diagram of the preparation method of the zwitterionic fluorescent compound ZWCYOH3 of Example 3;
[0080] FIG4 is a schematic diagram of the preparation method of the zwitterionic fluorescent compound ZWCYNH2 of Example 4;
[0081] FIG5 is a schematic diagram of the preparation method of the zwitterionic fluorescent compound ZWCYNH2P of Example 5;
[0082] FIG6 is a graph showing the ultraviolet absorption spectra of the zwitterionic fluorescent compounds ZWCYOH1, ZWCYOH2, ZWCYOH3, and ZWCYNH2 of Examples 1 to 4;
[0083] FIG7 is a fluorescence spectra of the zwitterionic fluorescent compounds ZWCYOH1, ZWCYOH2, ZWCYOH3, and ZWCYNH2 of Examples 1 to 4;
[0084] FIG8 shows the urine recovery rate within 24 hours after injection of the zwitterionic fluorescent compounds ZWCYOH1, ZWCYOH2, ZWCYOH3, and ZWCYNH2 of Examples 1 to 4;
[0085] FIG9 shows the fluorescence spectrum changes of the zwitterionic fluorescent compound ZWCYNH2P in Example 5 in response to protease in vitro;
[0086] FIG10 is an in vivo imaging diagram of the zwitterionic fluorescent compound ZWCYNH2P of Example 5 in an acute kidney injury mouse model;
[0087] FIG11 is an in vitro organ imaging diagram of the zwitterionic fluorescent compound ZWCYNH2P of Example 5 in an acute kidney injury mouse model. DETAILED DESCRIPTION
[0088] In order to more clearly and completely describe the technical solution of the present invention, the present invention is further described in detail through specific embodiments below. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not used to limit the present invention. Various changes can be made within the scope of the rights of the present invention.
[0089] Example 1
[0090] This embodiment provides a zwitterionic fluorescent compound, and a schematic diagram of a preparation method thereof is shown in FIG1 , which specifically includes the following steps:
[0091] 1. In a 100 mL double-necked round-bottom flask, under an argon atmosphere, add anhydrous dichloromethane (30 mL), N,N-dimethylformamide (6 mL, 77.5 mmol), and phosphorus tribromide (2 mL, 21.4 mmol) in that order. Stir at room temperature for 30 min, then add Compound A1 (2 mL, 19.3 mmol) and stir overnight at room temperature. Upon completion of the reaction, slowly add the reaction solution dropwise to an ice-cold saturated sodium bicarbonate solution and spin dry. Extract with ethyl acetate three times, dry over anhydrous sodium sulfate, and spin dry to obtain Compound B1 as a light yellow to brown oily liquid. This solution can be directly used in the next step without further purification.
[0092] 2. In a 100 mL double-necked round-bottom flask, under argon atmosphere, compound C1 (741 mg, 4.9 mmol), cesium carbonate (3.9 g, 12.1 mmol), compound B1 (764 mg, 4.1 mmol), and N,N-dimethylformamide (20 mL) were added sequentially and stirred at room temperature overnight. After the reaction, the mixture was spin-dried and extracted three times with ethyl acetate. After drying over anhydrous sodium sulfate, the mixture was spin-dried. The crude product was purified by column chromatography using a 15:1 ratio of petroleum ether to ethyl acetate. The purified product was collected and spin-dried to obtain compound D1 (560 mg, 58% yield) as a light yellow to brown solid. 1 H NMR (400MHz, CDCl3): δ10.32(s,1H),7.08(d,J=9.1Hz,1H),6.69–6.63(m,3H),3.84( s,2H),2.60–2.54(m,1H),2.47–2.41(m,1H),1.74–1.68(m,1H).LRMS(ESI)m / z:[M+H] + Calcd for C 15 H 15 O3243.10;Found 243.10.。
[0093] 3. To a 100 mL round-bottom flask, add compound E1 (3.76 g, 20 mmol), acetic acid (30 mL), compound F1 (3.2 mL, 30 mmol), and anhydrous sodium acetate (3.2 g, 38 mmol) in that order. Heat to 80°C in an oil bath and allow to react overnight. After the reaction, apply the sample directly to column chromatography without further treatment. Elution with dichloromethane:methanol = 15:1 yields the desired product. Spin dry to obtain compound G1 (4.0 g, 84% yield) as a pink powder. 1 H NMR (400MHz, DMSO-d6): δ7.63 (s, 1H), 7.55 (d, J = 7.9Hz, 1H), 7.34 (d, J = 7.9Hz, 1H), 2.21 (s, 3H), 1.25 (s, 6H). LRMS (ESI) m / z: [M+H] + Calcd for C 11 H 14 NO3S 240.07; Found 240.19.
[0094] 4. To a 100 mL round-bottom flask, add Compound G1 (1.5 g, 6.0 mmol), Compound H1 (3.1 g, 12.0 mmol), and toluene (35 mL) in that order. Heat in an oil bath to 100°C and react for 24 h. After the reaction, spin dry and wash with dichloromethane to obtain Compound I1 as a pink powder. This was used directly in the next reaction without further purification.
[0095] 5. In a 50 mL round-bottom flask, under an argon atmosphere, compound I1 (170 mg, 0.5 mmol), compound D1 (137 mg, 0.6 mmol), anhydrous sodium acetate (246 mg, 3.0 mmol), and anhydrous ethanol (15 mL) were added sequentially. The mixture was heated to 55°C in an oil bath and allowed to react overnight. After completion of the reaction, the mixture was spin-dried to dryness. Boron tribromide (1.5 mL, 15.6 mmol) was added under an ice bath and stirred overnight. After completion of the reaction, the reaction mixture was slowly added dropwise to an ice-cold saturated sodium bicarbonate solution, spin-dried to dryness, and separated by HPLC to obtain compound J1 (90 mg, 33% yield), a green powder, a zwitterionic fluorescent compound designated as ZWCYOH1. 1 H NMR (400MHz, DMSO-d6): δ11.02(s,1H),8.62(d,J=14.6Hz,1H),7.91(s,1H),7.7 3(d,J=8.2Hz,1H),7.68(s,1H),7.56(dd,J=16.6,8.5Hz,2H),7.02(s,1H),6.90( dd,J=8.5,2.2Hz,1H),6.45(d,J=14.6Hz,1H),4.37(t,J=7.3Hz,2H),3.08(s,9H) ,2.80–2.67(m,4H),2.21(s,2H),1.78(s,6H),1.23(s,4H).LRMS(ESI)m / z:[M+H] + Calcd for C 31 H 38 N2O5S 550.25; Found 549.92.
[0096] The structural formula of the zwitterionic fluorescent compound provided in this embodiment is as follows:
[0097] It can be used as a constantly fluorescent probe.
[0098] Example 2
[0099] This embodiment provides a zwitterionic fluorescent compound, the preparation method of which is shown in FIG2 , specifically comprising the following steps:
[0100] 1. To a 50 mL round-bottom flask, add compound A2 (576 mg, 4.0 mmol), tert-butanol (15 mL), potassium tert-butoxide (538 mg, 4.8 mmol), and compound B2 (0.4 mL, 4.0 mmol) in this order. Stir at 70°C overnight. After the reaction is complete, spin dry, extract three times with n-hexane, remove the aqueous phase, adjust the solution pH to 1, spin dry, and dry. Add methanol (5 mL) to redissolve, filter, and take the filtrate directly for the next step.
[0101] 2. Add the methanol solution of compound C2 (i.e., the filtrate obtained in step 1) to a 50 mL round-bottom flask, followed by 1 mol / L sodium hydroxide solution (14 mL, 14.0 mmol). Heat the oil bath to 70°C and allow to react overnight. After the reaction is complete, adjust the solution pH to 1 by spin drying, spin dry, and dry. Add 20 mL of acetone to redissolve, filter, and spin dry the filtrate to obtain compound D2 (300 mg, 36% yield). LRMS (ESI) m / z: [M+H] + Calcd for C8H 17 O4S 209.08;Found 209.12.
[0102] 3. To a 50 mL round-bottom flask, add compound D2 (300 mg, 1.4 mmol), compound E2 (188 mg, 1.0 mol), and acetic acid (10 mL) in sequence. Heat to 95°C in an oil bath and reflux overnight. After the reaction, wash with isopropanol and filter. The residue is compound F2 (176 mg, 48% yield). LRMS (ESI) m / z: [M+H] + Calcd for C 14 H 19 NO6S2362.07; Found 362.23.
[0103] 4. To a 100 mL round-bottom flask, add compound F2 (1.3 g, 3.0 mmol), o-dichlorobenzene (30 mL), compound H1 (3.2 g, 12.0 mmol), and sodium iodide (900 mg, 6 mmol) in that order. Heat in an oil bath to 100°C and react for 24 h. After the reaction, spin dry and wash with ethyl acetate to obtain compound H2. This product can be used directly in the next step without further purification.
[0104] 5. To a 100 mL double-necked round-bottom flask, add compound H2 (567 mg, 1.2 mmol), compound D1 (410 mg, 1.8 mmol, prepared in Example 1), anhydrous sodium acetate (590 mg, 2.4 mmol), and anhydrous ethanol (30 mL) in this order. Heat in an oil bath to 55°C and allow to react overnight. After completion of the reaction, spin dry the mixture. Add boron tribromide (1.5 mL, 15.6 mmol) in an ice bath and continue stirring overnight. After completion of the reaction, slowly add the reaction solution dropwise to an ice-cold saturated sodium bicarbonate solution, spin dry, and separate by HPLC to obtain compound I2 (249 mg, 31% yield), a green powder, a zwitterionic fluorescent compound designated as ZWCYOH2. 1 H NMR (500MHz, Methanol-d4): δ8.55(s,1H),7.91(d,J=10.4Hz,1H),7.80(s,2H),7.53(d,J=9.0Hz,1H),7.41(d, J=8.6Hz,1H),6.86(d,J=9.0Hz,2H),6.77(s,2H),6.61(d,J=8.1Hz,2H),6.29(d,J=13.5Hz,3H),4.57(s,1H),4 .27–4.20(m,1H),3.85(s,1H),3.67(s,1H),3.19(dd,J=26.2,16.2Hz,1H),2.82(s,1H),2.66(d,J=23.7Hz,1H) ,2.33(s,1H),1.95(s,1H),1.81(s,1H),1.60(s,1H),1.31(d,J=14.9Hz,1H),1.14(s,1H).LRMS(ESI)m / z:[M+H] + Calcd for C 34 H 43 N2O8S2671.25; Found 671.77.
[0105] The structural formula of the zwitterionic fluorescent compound provided in this embodiment is as follows:
[0106] It can be used as a constantly fluorescent probe.
[0107] Example 3
[0108] This embodiment provides a zwitterionic fluorescent compound, the preparation method of which is shown in FIG3 , specifically comprising the following steps:
[0109] 1. To a 100 mL round-bottom flask, add compound A3 (10.3 g, 65.0 mmol), water (16 mL), and sodium hydroxide (2.6 g, 65.0 mmol) in sequence. Stir at room temperature for 5 h. After the reaction is complete, allow the strata to separate. Collect the organic phase into a new 100 mL round-bottom flask, add 1,2-dichloroethane (20 mL) and compound B3 (8.5 mL, 97.5 mmol), heat to 50°C in an oil bath, and react overnight. After the reaction is complete, wash with ethyl acetate to obtain compound C3 (13.7 g, 87% yield). 1 H NMR (400MHz, D2O): δ3.64(s,2H),3.44(dd,J=8.4,5.6Hz,4H),3.07(s,6H),2.91(s,2H),2.19(dd,J=11.9,7.1Hz,4H).
[0110] 2. To a 100 mL round-bottom flask, add compound G1 (4.0 g, 16.0 mmol, prepared in Example 1), o-dichlorobenzene (30 mL), compound C3 (4.0 g, 12.0 mmol), and sodium iodide (1.8 g, 12 mmol) in sequence. Heat to 100°C in an oil bath and react for 24 h. After the reaction, spin dry and separate by HPLC to obtain compound D3 (3.0 g, 42% yield), a pink solid. 1 H NMR (500MHz, Methanol-d4): δ8.23–8.09(m,2H),8.06(s,1H),4.84–4.61(m,1H),3.88–3.76(m,2H),3.72–3.55(m,1H),3.46– 3.37(m,1H),3.27–3.21(m,1H),2.92(s,1H),2.60(d,J=47.6Hz,1H),2.32(d,J=6.4Hz,1H),1.74(s,4H).LRMS(ESI)m / z:[MH] - Calcd for C 19 H 29 N2O6S2445.15;Found 445.22.
[0111] 3. To a 100 mL double-necked round-bottom flask, add compound D3 (760 mg, 1.7 mmol), compound D1 (470 mg, 2.1 mmol, prepared in Example 1), anhydrous sodium acetate (845 mg, 10 mmol), and N,N-dimethylformamide (5 mL) in this order. Heat in an oil bath to 55°C and react overnight. After completion of the reaction, spin dry the mixture. Add boron tribromide (1.5 mL, 15.6 mmol) in an ice bath and continue stirring overnight. After completion of the reaction, slowly add the reaction mixture dropwise to an ice-cold saturated sodium bicarbonate solution, spin dry, and separate by HPLC to obtain compound E3 (379 mg, 34% yield), a green powder, a zwitterionic fluorescent compound designated as ZWCYOH3. 1 H NMR (500MHz, Methanol-d4): δ8.29(d,J=13.7Hz,1H),7.86(s,1H),7.82(d,J=7.8Hz, 1H),7.78(d,J=6.7Hz,1H),7.45(d,J=9.0Hz,1H),7.22(d,J=8.3Hz,1H),6.76(dd,J= 9.1,1.6Hz,1H),6.56(s,1H),6.04(d,J=13.5Hz,1H),3.63–3.54(m,6H),3.16(s,6H) ,2.83(dd,J=23.2,16.7Hz,12H),2.26(dd,J=20.9,7.4Hz,6H).LRMS(ESI)m / z:[M+H] + Calcd for C 33 H 41 N2O8S2657.23;Found 657.68.
[0112] The structural formula of the zwitterionic fluorescent compound provided in this embodiment is as follows:
[0113] It can be used as a constantly fluorescent probe.
[0114] Example 4
[0115] This embodiment provides a zwitterionic fluorescent compound, the preparation method of which is shown in FIG4 , specifically comprising the following steps:
[0116] 1. To a 100 mL double-necked round-bottom flask, under argon atmosphere, add Compound A4 (500 mg, 3.0 mmol), cesium carbonate (3.6 g, 10.8 mmol), N,N-dimethylformamide (20 mL), and Compound B1 (1.4 g, 5.0 mmol, prepared in Example 1) in this order. Stir the reaction mixture at room temperature overnight. Extract three times with ethyl acetate, dry over anhydrous sodium sulfate, and spin dry. The crude product is purified by column chromatography using a 10:1 ratio of petroleum ether to ethyl acetate. The purified product is collected and spin dried to obtain Compound B4 (629 mg, 82% yield) as a light yellow to brown solid. 1 H NMR (400MHz, CDCl3): δ10.38(s,1H),7.93(d,J=10.2Hz,2H),7.28(d,J=8.2Hz,1H),6.70( s,1H),2.68–2.62(m,2H),2.47(t,J=5.7Hz,2H),1.80–1.73(m,2H).LRMS(ESI)m / z:[M+H] + Calcd for C 14 H 11 NO4258.08;Found 258.26.。
[0117] 2. In a 100 mL double-necked round-bottom flask, under argon atmosphere, add compound D3 (1.0 g, 2.2 mmol, prepared in Example 3), compound B4 (310 mg, 1.2 mmol), anhydrous sodium acetate (590 mg, 7.2 mmol), N,N-dimethylformamide (15 mL), and acid anhydride (15 mL). Heat the mixture to 55°C in an oil bath and allow to react overnight. After completion, spin dry. Add methanol (30 mL) and a concentrated hydrochloric acid solution of stannous chloride (4.7 g, 25.0 mmol). Heat the mixture to 55°C in an oil bath and allow to react overnight. After completion, add saturated sodium bicarbonate solution dropwise until the pH reaches 8. Spin dry and separate by HPLC to obtain compound C4 (366 mg, 56% yield), a green powder, a zwitterionic fluorescent compound designated ZWCYNH2. 1H NMR (500MHz, Methanol-d4): δ8.50(d,J=13.5Hz,1H),7.78(dd,J=30.2,13.5Hz,2H),7.43(d,J=8.7Hz,1H),7 .28(d,J=8.1Hz,1H),7.16(s,1H),7.01(s,1H),6.83(d,J=8.5Hz,1H),6.14(d,J=13.7Hz,1H),3.60–3.46(m, 4H),3.07(s,3H),2.79(d,J=12.3Hz,2H),2.72(d,J=22.0Hz,2H),2.11(t,J=7.2Hz,3H),1.86(s,2H),1.74(d ,J=8.9Hz,2H),1.51(dd,J=14.1,7.1Hz,3H),1.47–1.37(m,3H),1.21(d,J=34.8Hz,6H).LRMS(ESI)m / z:[MH] - Calcd for C 33 H 40 N3O7S2654.24; Found 654.20.
[0118] The structural formula of the zwitterionic fluorescent compound provided in this embodiment is as follows:
[0119] It can be used as a constantly fluorescent probe.
[0120] Example 5
[0121] This embodiment provides a zwitterionic fluorescent compound, which is obtained by attaching a biomarker response group to ZWCYNH2 in Example 4. The schematic diagram of the preparation method is shown in Figure 5, and specifically includes the following steps:
[0122] 1. To a 50 mL round-bottom flask, add compound A5 (130 mg, 0.2 mmol), O-(7-azabenzotriazole-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (140 mg, 0.4 mmol), anhydrous N,N-dimethylformamide (15 mL), and N,N-diisopropylethylamine (30 μL, 0.2 mmol) in that order. After stirring at room temperature for 20 minutes, add compound C4 (50 mg, 0.08 mmol) obtained in Example 4. Continue stirring at room temperature and allow the reaction to proceed overnight. After the reaction is complete, spin dry the product and proceed to the next step without further treatment.
[0123] 5. Add Compound B5 and trifluoroacetic acid (1 mL, 13 mmol) to a 25 mL round-bottom flask. Stir for 8 h. Upon completion of the reaction, spin dry the mixture and separate by HPLC to obtain Compound C5 (26 mg, 29% yield) as a blue powder. This is a zwitterionic fluorescent compound designated ZWCYNH2P. 1 H NMR (500MHz, D2O): δ8.58(d,J=14.3Hz,1H),8.44(s,1H),7.95(s,1H),7.89(d,J=8.3Hz,1H),7.81(s,1H),7.38(d,J=8.3Hz,1H),7.33–7 .25(m,2H),6.32(d,J=14.5Hz,1H),4.71(dd,J=9.7,6.1Hz,363H),4.64–4.56(m,5H),4.42–4.32(m,3H),4.22(dd,J=13.7,7.5Hz,4H),4 .02(d,J=7.5Hz,1H),3.69(d,J=7.2Hz,2H),3.66–3.59(m,2H),3.56–3.43(m,4H),3.10(s,2H),2.92(dd,J=18.2,11.0Hz,2H),2.71–2.5 8(m,4H),2.36–2.13(m,6H),1.99(s,1H),1.72(s,2H),1.57(d,J=4.4Hz,2H),1.40–1.20(m,6H),0.85–0.71(m,4H).LRMS(ESI)m / z:[MH] - Calcd for C 54 H 72 N7O 17 S21154.45;Found 1154.45.。
[0124] The structural formula of the zwitterionic fluorescent compound provided in this embodiment is as follows:
[0125] It can be used as an activatable fluorescent probe.
[0126] Performance Testing
[0127] 1. Spectral Analysis: PBS and methanol solutions of the constantly luminous fluorescent probes ZWCYOH1, ZWCYOH2, ZWCYOH3, and ZWCYNH2 were prepared at 0.05 mg / mL. The absorption spectra of each sample were measured from 400 to 900 nm using a UV spectrometer, and the fluorescence spectra of each sample were measured using a fluorescence spectrometer (excitation wavelength: 660 nm). The test results are shown in Figures 6 and 7. Since the fluorophores of each probe are all hemicyanine structures, there is no significant difference in the maximum absorption and emission wavelengths of the spectra.
[0128] 2. Renal Clearance Efficiency Test: A 0.05 mg / mL solution of the constantly luminous fluorescent probes ZWCYOH1, ZWCYOH2, ZWCYOH3, and ZWCYNH2 in PBS was prepared. Twelve Balb / c mice were randomly divided into three groups of three mice each. 75 μL of the probe solution was injected into the tail vein of each mouse. After injection, the mice were individually placed in clean metabolic cages. Urine was collected within 24 hours and the volume was recorded. A standard curve comparing probe concentration and chromatographic peak area was prepared using high-performance liquid chromatography (HPLC) to calculate the recovery of the probes in mouse urine.
[0129] The test results are shown in Figure 8. ZWCYOH1, ZWCYOH2, ZWCYOH3, and ZWCYNH2 can all be metabolized through the urinary system and present in the excreted urine. Among them, the constantly-on probes ZWCYOH2, ZWCYOH3, and ZWCYNH2 have a more balanced charge distribution and higher urine recoveries of 88%, 91%, and 93%, respectively. This demonstrates that the zwitterionic fluorescent probes provided by the present invention have good renal clearance efficiency and can be used for the detection of urinary system diseases.
[0130] The renal clearance efficiency test results of ZWCYNH2P were similar, with a recovery rate of 91%.
[0131] 3. Activation Probe Responsiveness Test: A 10 μM solution of the activation probe ZWCYNH2P was incubated with the apoptotic protease caspase-8 in a 37°C buffer solution. The fluorescence spectrum of the solution was measured. The test results, shown in Figure 9, show that the probe's polypeptide sequence is recognized and cleaved by caspase-8, resulting in a red-shift in the fluorescence emission wavelength and an increase in fluorescence intensity.
[0132] 4. Establishment of acute kidney injury mouse model: 18 Balb / c mice were randomly divided into 6 groups, namely blank control group (control group), NAC control group, and model groups (12h group, 24h group, 48h group, 72h group), with three mice in each group. (1) Control group: intraperitoneal injection of 0.4mL normal saline; (2) AKI (acute kidney injury) model group: intraperitoneal injection of 20mg / kg cisplatin solution, and imaging examination was performed 12h, 24h, 48h, and 72h after injection; (3) NAC group: tail vein injection of 400mg / kg NAC solution, 30min later intraperitoneal injection of 20mg / kg cisplatin solution, and imaging examination was performed 48h after cisplatin injection. Finally, the mice were euthanized and imaging of each organ was performed.
[0133] The test results are shown in Figure 10. After the ZWCYNH2P probe was injected into the body, caspase-8 expression was relatively low in the control and 12-hour groups, as the kidneys were normal and free of lesions. Consequently, the probe's fluorescence intensity was also low. However, as time passed after cisplatin injection, cisplatin gradually damaged kidney tissue, inducing acute kidney injury and leading to a gradual increase in caspase-8 protein expression in the kidneys. Upon injection, the probe's peptide sequence was recognized and cleaved by the caspase-8 protease, exposing free amino groups and restoring the probe's "D-π-A" structure, resulting in strong fluorescence.
[0134] The test results, shown in Figure 11, show that the liver signal is weaker than the kidney signal, demonstrating that the probe is primarily metabolized by the kidneys, not the liver. Furthermore, the kidney signal in each group increased with increasing cisplatin injection duration, indicating a gradual increase in capase-8 protein expression, potentially enabling early diagnosis of the disease.
[0135] Obviously, the above embodiments of the present invention are merely examples for the purpose of clearly illustrating the present invention, and are not intended to limit the embodiments of the present invention. Those skilled in the art will appreciate that other variations or modifications can be made based on the above description. It is not necessary and impossible to enumerate all embodiments here. Any modifications, equivalent substitutions, and improvements made within the spirit and principles of the present invention shall be included within the scope of protection of the claims of the present invention.
Claims
1. A zwitterionic fluorescent compound, characterized in that: It has a structure shown in any one of formula (I) to formula (V): Among them, R1 is -COO - , -SCN, -N3 or R2 is -OH, -NH2, A is a self-eliminating group, B is a biomarker response group; n is an integer of 0 to 50, n1 is an integer of 0 to 20, and n2 is an integer of 0 to 20.
2. The zwitterionic fluorescent compound according to claim 1, characterized in that: The self-eliminating group A is 3. The zwitterionic fluorescent compound according to claim 1, characterized in that: The biomarker response group B is 4. The zwitterionic fluorescent compound according to claim 1, characterized in that: The n is an integer of 1-20.
5. The zwitterionic fluorescent compound according to claim 1, characterized in that: Has the following structure:
6. The method for preparing the zwitterionic fluorescent compound according to any one of claims 1 to 5, characterized in that: The steps include: S1. Compound 1 represented by formula (1) and compound 6 represented by formula (6) undergo condensation reaction to obtain compound 8 represented by formula (8); or the compound 1 represented by formula (1) and the compound 7 represented by formula (7) undergo a condensation reaction to obtain the compound 9 represented by formula (9); Or the compound 2 represented by formula (2) and the compound 6 represented by formula (6) undergo a condensation reaction to obtain the compound 12 represented by formula (12); Or the compound 2 represented by formula (2) and the compound 7 represented by formula (7) undergo a condensation reaction to obtain the compound 13 represented by formula (13); Or the compound 3 represented by formula (3) and the compound 6 represented by formula (6) undergo condensation reaction to obtain the compound 16 represented by formula (16); Or the compound 3 represented by formula (3) and the compound 7 represented by formula (7) undergo condensation reaction to obtain the compound 17 represented by formula (17); Or the compound 4 represented by formula (4) and the compound 6 represented by formula (6) undergo condensation reaction to obtain the compound 20 represented by formula (20); Or the compound 4 represented by formula (4) and the compound 7 represented by formula (7) undergo condensation reaction to obtain the compound 21 represented by formula (21); Or the compound 5 represented by formula (5) and the compound 6 represented by formula (6) undergo condensation reaction to obtain the compound 24 represented by formula (24); Or the compound 5 represented by formula (5) and the compound 7 represented by formula (7) undergo condensation reaction to obtain the compound 25 represented by formula (25); S2. Compound 8 undergoes a demethylation protection reaction to obtain compound 10 represented by formula (10); Or compound 12 undergoes a demethylation protection reaction to obtain compound 14 represented by formula (14); Or compound 16 undergoes a demethylation protection reaction to obtain compound 18 represented by formula (18); Or compound 20 undergoes a demethylation protection reaction to obtain compound 22 represented by formula (22); Or compound 24 undergoes a demethylation protection reaction to obtain compound 26 represented by formula (26); Or compound 9 is subjected to reduction reaction to obtain compound 11 represented by formula (11); Or compound 13 is subjected to reduction reaction to obtain compound 15 represented by formula (15); Or compound 17 is subjected to reduction reaction to obtain compound 19 represented by formula (19); Or compound 21 is subjected to reduction reaction to obtain compound 23 represented by formula (23); Or compound 25 is subjected to reduction reaction to obtain compound 27 represented by formula (27); S3. Compound 10 undergoes a substitution reaction with R2-H to obtain a zwitterionic fluorescent compound as shown in formula (I); Or compound 14 undergoes a substitution reaction with R2-H to obtain a zwitterionic fluorescent compound as shown in formula (II); Or compound 18 undergoes a substitution reaction with R2-H to obtain a zwitterionic fluorescent compound as shown in formula (III); Or compound 22 undergoes a substitution reaction with R2-H to obtain a zwitterionic fluorescent compound as shown in formula (IV); Or compound 26 undergoes a substitution reaction with R2-H to obtain a zwitterionic fluorescent compound as shown in formula (V); Or compound 11 undergoes a condensation reaction with R2-H to obtain a zwitterionic fluorescent compound as shown in formula (I); Or compound 15 undergoes a condensation reaction with R2-H to obtain a zwitterionic fluorescent compound as shown in formula (II); Or compound 19 undergoes a condensation reaction with R2-H to obtain a zwitterionic fluorescent compound as shown in formula (III): Or compound 23 undergoes a condensation reaction with R2-H to obtain a zwitterionic fluorescent compound as shown in formula (IV); Or compound 27 undergoes a condensation reaction with R2-H to obtain a zwitterionic fluorescent compound as shown in formula (V) thing; 7. The method for preparing the zwitterionic fluorescent compound according to claim 6, characterized in that: The condensation reaction in step S1 is carried out at a temperature of 45 to 100° C. and for a time of 5 to 12 hours.
8. The method for preparing the zwitterionic fluorescent compound according to claim 6, characterized in that: The temperature of the demethylation reaction in step S2 is 0-30° C., and the time is 5-12 h; the temperature of the reduction reaction in step S2 is 45-100° C., and the time is 5-12 h.
9. The method for preparing the zwitterionic fluorescent compound according to claim 6, characterized in that: The temperature of the substitution reaction in step S3 is 45-100° C., and the time is 5-12 hours; the temperature of the condensation reaction in step S3 is 0-45° C., and the time is 8-24 hours.
10. Use of the zwitterionic fluorescent compound according to any one of claims 1 to 5 or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer or tautomer thereof in the preparation of a fluorescent probe.
Citation Information
Patent Citations
Synthesis and applications of novel visible light and near-infrared fluorescent dye
CN110642848A
Dihydroxanthene / benzo[cd]indole heterocomplex fluorescent probe, and preparation method and application thereof
CN113735839A
Biomarker response type fluorescent tracer as well as preparation method and application thereof
CN114377152A
Near-infrared molecules with PTT and PDT effects and application thereof
CN115368347A
Near-infrared two-region fluorescent compound as well as preparation method and application thereof
CN115947777A
